

From: Maruna, Thomas
Sent: Thursday, May 12, 2016 4:13 PM
To: KevinDarryl.White@cslbehring.com; 'Angela.Azzara@cslbehring.com'
Cc: Frost, Mitchell M; Khrenov, Alexey (CBER)
Subject: FDA Request for Info and DHCP Letter - BL 125591/0 -
Antihemophilic Factor
(Recombinant), Single Chain (Please respond by May 17, 2016)
Attachments: draft-dhcp-letter.doc

Importance: High

Our Reference: BL 125591/0

CSL Behring Recombinant Facility AG
Attention: Kevin D. White, MBA, RAC
May 12, 2016
Sent by email

Dear Mr. White:

We are reviewing your May 29, 2015, biologics license application (BLA) for Antihemophilic Factor (Recombinant), Single Chain. We are providing the revised labeling for your review and acceptance:

The review of this submission is on-going and issues may be added, expanded upon, or modified as we continue to review this submission.

Please submit your response to this information request as an amendment to this file as soon as possible, but no later than May 17, 2016, referencing the date of this request. Please include both a red-line strike out and clean copy of the revised DHCP Letter in WORD format. If you anticipate you will not be able to respond by this date, please contact the Agency immediately so a new response date can be identified.

The action due date for this file is May 28, 2016.

If you have any questions during this week, please contact me.

Very Respectfully,

Thomas J. Maruna, MSc, MLS(ASCP), CPH
Lieutenant, U.S. Public Health Service
Senior Regulatory Management Officer
Food and Drug Administration
Center for Biologics Evaluation and Research
Office of Blood Research and Review
10903 New Hampshire Ave.
Silver Spring, MD 20993

thomas.maruna@fda.hhs.gov
O: (240) 402-8454
www.usphs.gov

"THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.